Addex Therapeutics (ADXN) EBIT (2022 - 2025)
Historic EBIT for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to -$870270.5.
- Addex Therapeutics' EBIT fell 2118.28% to -$870270.5 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 837.02%. This contributed to the annual value of -$3.1 million for FY2024, which is 2540.47% down from last year.
- According to the latest figures from Q3 2025, Addex Therapeutics' EBIT is -$870270.5, which was down 2118.28% from -$885260.4 recorded in Q2 2025.
- Over the past 5 years, Addex Therapeutics' EBIT peaked at -$397495.9 during Q1 2023, and registered a low of -$21.3 million during Q4 2022.
- Over the past 4 years, Addex Therapeutics' median EBIT value was -$902903.2 (recorded in 2024), while the average stood at -$3.4 million.
- Its EBIT has fluctuated over the past 5 years, first skyrocketed by 9401.63% in 2023, then plummeted by 12714.78% in 2024.
- Over the past 4 years, Addex Therapeutics' EBIT (Quarter) stood at -$21.3 million in 2022, then surged by 88.13% to -$2.5 million in 2023, then dropped by 24.37% to -$3.1 million in 2024, then soared by 72.33% to -$870270.5 in 2025.
- Its EBIT was -$870270.5 in Q3 2025, compared to -$885260.4 in Q2 2025 and -$674315.2 in Q1 2025.